Last reviewed · How we verify
IV Anti-thymocyte globuline
At a glance
| Generic name | IV Anti-thymocyte globuline |
|---|---|
| Also known as | Anti-thymocyte globuline |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies (PHASE2)
- Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Anti-thymocyte globuline CI brief — competitive landscape report
- IV Anti-thymocyte globuline updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI